RxSight, Inc. Appoints Raymond W. Cohen to Its Board of Directors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 04 2025
0mins
Source: Newsfilter
Appointment of Raymond W. Cohen: RxSight, Inc. has appointed Raymond W. Cohen to its Board of Directors, recognizing his extensive experience in medical technology and leadership roles, which will aid the company's growth strategy and expansion of its Light Adjustable Lens system for cataract surgery patients.
Cohen's Background and Vision: With over 40 years in the industry, Cohen has successfully led companies like Axonics, generating significant revenue and growth. He aims to leverage his expertise to enhance RxSight's position in the premium intraocular lens market and support its mission for improved patient outcomes.
Analyst Views on KMTS
Wall Street analysts forecast KMTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KMTS is 30.00 USD with a low forecast of 28.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 22.980
Low
28.00
Averages
30.00
High
32.00
Current: 22.980
Low
28.00
Averages
30.00
High
32.00
About KMTS
Kestra Medical Technologies, Ltd. is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intelligent and connected. The Company has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The Company's Cardiac Recovery System platform includes ASSURE WCD, which is a wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA). Its Cardiac Recovery System platform also includes fully integrated digital solutions and services such as the ASSURE patient application, Kestra CareStation remote patient data platform, Heart Alert Services, and ASSURE Assist services and ASSURE wearable ECG.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
